Cheap, 'generic' drug reduces COVID-19 death risk by 75 percent, trials suggest
Ivermectin, a cheap and "generic" antiparasitic drug "used all over the world," may significantly reduce the risk of death in patients suffering from moderate to severe cases of COVID-19, researchers have found.
The University of Liverpool's Andrew Hill and others carried out a meta-analytical breakdown of 18 studies that showed the drug — which is off-patent and commonly used to treat lice and scabies, as well as some more serious parasites — appears to reduce inflammation and eliminate the coronavirus swiftly, the Financial Times reports. In six of those trials, the mortality risk was cut by 75 percent in patients with more serious COVID-19 infections. The research team has also theorized the drug could also make it harder for infected people to transmit the virus.
Hill said he's encouraged by the findings, but further studies are needed, especially since several of those in the analysis were not peer-reviewed. FT also notes that meta-analyses, which look at many studies at once, can be prone to errors. Read more at the Financial Times.
More stories from theweek.com
7 brutally funny cartoons about Trump's White House exit
Bernie Sanders steals the inauguration with his grumpy chic outfit
New coronavirus variants may cut vaccine effectiveness
